- Previous Close
106.94 - Open
106.76 - Bid 107.72 x --
- Ask 107.78 x --
- Day's Range
105.00 - 107.90 - 52 Week Range
53.00 - 107.90 - Volume
84,186 - Avg. Volume
617,616 - Market Cap (intraday)
25.605B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Mar 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
101.85
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
www.galderma.com6,545
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GALD.SW
View MorePerformance Overview: GALD.SW
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GALD.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GALD.SW
View MoreValuation Measures
Market Cap
25.41B
Enterprise Value
27.74B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.33%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.32B
Net Income Avi to Common (ttm)
-14.2M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
385M
Total Debt/Equity (mrq)
38.61%
Levered Free Cash Flow (ttm)
--